Kuehn Law is investigating whether officers and directors of Viking Therapeutics breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term VKTX stockholders to participate in shareholder litigation, offering free consultations with no obligation.

Kuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.

Viking Therapeutics' lead drug candidate VK2735, a dual GLP-1/GIP agonist, shows promise in the competitive weight-loss market with potential for rapid weight loss via injectable form followed by oral maintenance. However, the company faces significant risks including safety concerns from phase 2 trials, long development timelines (phase 3 results not expected until 2027-2028), and likely acquisition by a larger pharmaceutical company if successful.

Viking Therapeutics' obesity drug candidate VK2735 could potentially grow a $1,000 investment to $2,500-$3,400 by 2030 under favorable conditions, but faces significant competition from established players Eli Lilly and Novo Nordisk. The company will likely need to dilute shares through fundraising, and the drug must capture at least 1% market share to justify current valuations. Clinical trial failure could reduce investments by 60-80%.

Viking Therapeutics, a $4.3B biotech company, is developing VK2735, a weight loss drug candidate in late-stage trials. Bulls cite the massive $100B obesity drug market opportunity, potential acquisition interest, and positive historical stock reactions to data releases. Bears highlight competition from pharma giants Eli Lilly and Novo Nordisk, pipeline risk, and the stock's 40% year-over-year gain. The analyst believes the bull case outweighs the bear case, suggesting Viking could reach $50 if upcoming data proves positive.

Viking Therapeutics stock rose 19.2% in June driven by optimism over its weight-loss drug pipeline, particularly VK2735, a GLP-1/GIP agonist showing steeper weight loss rates than competitors. The company also initiated a Phase 1 trial for VK3019, a new class of weight-loss drug with a different mechanism. Investors await Phase 3 trial results expected in 2027-2028 and Phase 1 maintenance trial results in Q3 2026.

Eli Lilly stock reached a new all-time high, driven by its blockbuster weight loss treatment. The company holds dominant market share in the weight loss drug category and is being positioned as a clear winner in the GLP-1 drug space, with analysts highlighting its strong performance at industry conferences.

The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.

The GLP-1 drug market is projected to reach $185 billion by 2033. Eli Lilly dominates with its successful Mounjaro and Zepbound drugs generating $13 billion in Q1 revenue, but trades at a premium 39x earnings. Viking Therapeutics, a smaller biotech with no approved products yet, offers higher risk/reward potential with its promising VK2735 candidate in phase 3 trials. The author recommends Viking as the better buy for risk-tolerant investors seeking significant upside.

The article recommends Amazon and Costco as long-term 'set and forget' stocks suitable for 20-year holding periods. Amazon benefits from its dominance in e-commerce and cloud computing (AWS), which is experiencing explosive growth from the AI boom. Costco's membership-based model with high renewal rates (92% in U.S./Canada) and low-margin warehouse sales offset by high-margin membership fees provide stability across market conditions.